ECCO 2017 | Pros and cons of biomarker testing
Werner Lichtenegger, MD, PhD from Charité University Hospital, Berlin, Germany, discusses biomarker testing at the European Cancer Congress of the European Cancer Organisation (ECCO) 2017 in Amsterdam, Netherlands. The testing of biomarkers poses a problem in that it is not known if what is being tested is the right thing. A major benefit of biomarker testing, however, is that more effective treatments can be given to certain subgroups, improving their outcome. He does state that biomarker testing is still new, and that there is a lot more to discover.
Get great new content delivered to your inboxSign up